ER/PR testing identifies breast cancer patients who are candidates for hormonal therapy, which can substantially improve their survival.[1, 2] Human epidermal growth factor receptor-2 (HER2) protein is overexpressed and HER2 gene is amplified in greater than 20% of the invasive breast cancers. Here, ESR1 is linked to breast carcinoma.